Cargando…

Serum Mature BDNF Level Is Associated with Remission Following ECT in Treatment-Resistant Depression

The search for a biological marker predicting the future failure or success of electroconvulsive therapy (ECT) remains highly challenging for patients with treatment-resistant depression. Evidence suggests that Brain-Derived Neurotrophic Factor (BDNF), a protein known to be involved in brain plastic...

Descripción completa

Detalles Bibliográficos
Autores principales: Psomiades, Marion, Mondino, Marine, Galvão, Filipe, Mandairon, Nathalie, Nourredine, Mikail, Suaud-Chagny, Marie-Françoise, Brunelin, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870188/
https://www.ncbi.nlm.nih.gov/pubmed/35203890
http://dx.doi.org/10.3390/brainsci12020126
_version_ 1784656678520619008
author Psomiades, Marion
Mondino, Marine
Galvão, Filipe
Mandairon, Nathalie
Nourredine, Mikail
Suaud-Chagny, Marie-Françoise
Brunelin, Jérôme
author_facet Psomiades, Marion
Mondino, Marine
Galvão, Filipe
Mandairon, Nathalie
Nourredine, Mikail
Suaud-Chagny, Marie-Françoise
Brunelin, Jérôme
author_sort Psomiades, Marion
collection PubMed
description The search for a biological marker predicting the future failure or success of electroconvulsive therapy (ECT) remains highly challenging for patients with treatment-resistant depression. Evidence suggests that Brain-Derived Neurotrophic Factor (BDNF), a protein known to be involved in brain plasticity mechanisms, can play a key role in both the clinical efficacy of ECT and the pathophysiology of depressive disorders. We hypothesized that mature BDNF (mBDNF), an isoform of BDNF involved in the neural plasticity and survival of neural networks, might be a good candidate for predicting the efficacy of ECT. Total BDNF (tBDNF) and mBDNF levels were measured in 23 patients with severe treatment-resistant depression before (baseline) they received a course of ECT. More precisely, tBDNF and mBDNF measured before ECT were compared between patients who achieved the criteria of remission after the ECT course (remitters, n = 7) and those who did not (non-remitters, n = 16). We found that at baseline, future remitters displayed significantly higher mBDNF levels than future non-remitters (p = 0.04). No differences were observed regarding tBDNF levels at baseline. The multiple logistic regression model controlled for age and sex revealed that having a higher baseline mBDNF level was significantly associated with future remission after ECT sessions (odd ratio = 1.38; 95% confidence interval = 1.07–2.02, p = 0.04). Despite the limitations of the study, current findings provide additional elements regarding the major role of BDNF and especially the mBDNF isoform in the clinical response to ECT in major depression.
format Online
Article
Text
id pubmed-8870188
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88701882022-02-25 Serum Mature BDNF Level Is Associated with Remission Following ECT in Treatment-Resistant Depression Psomiades, Marion Mondino, Marine Galvão, Filipe Mandairon, Nathalie Nourredine, Mikail Suaud-Chagny, Marie-Françoise Brunelin, Jérôme Brain Sci Article The search for a biological marker predicting the future failure or success of electroconvulsive therapy (ECT) remains highly challenging for patients with treatment-resistant depression. Evidence suggests that Brain-Derived Neurotrophic Factor (BDNF), a protein known to be involved in brain plasticity mechanisms, can play a key role in both the clinical efficacy of ECT and the pathophysiology of depressive disorders. We hypothesized that mature BDNF (mBDNF), an isoform of BDNF involved in the neural plasticity and survival of neural networks, might be a good candidate for predicting the efficacy of ECT. Total BDNF (tBDNF) and mBDNF levels were measured in 23 patients with severe treatment-resistant depression before (baseline) they received a course of ECT. More precisely, tBDNF and mBDNF measured before ECT were compared between patients who achieved the criteria of remission after the ECT course (remitters, n = 7) and those who did not (non-remitters, n = 16). We found that at baseline, future remitters displayed significantly higher mBDNF levels than future non-remitters (p = 0.04). No differences were observed regarding tBDNF levels at baseline. The multiple logistic regression model controlled for age and sex revealed that having a higher baseline mBDNF level was significantly associated with future remission after ECT sessions (odd ratio = 1.38; 95% confidence interval = 1.07–2.02, p = 0.04). Despite the limitations of the study, current findings provide additional elements regarding the major role of BDNF and especially the mBDNF isoform in the clinical response to ECT in major depression. MDPI 2022-01-18 /pmc/articles/PMC8870188/ /pubmed/35203890 http://dx.doi.org/10.3390/brainsci12020126 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Psomiades, Marion
Mondino, Marine
Galvão, Filipe
Mandairon, Nathalie
Nourredine, Mikail
Suaud-Chagny, Marie-Françoise
Brunelin, Jérôme
Serum Mature BDNF Level Is Associated with Remission Following ECT in Treatment-Resistant Depression
title Serum Mature BDNF Level Is Associated with Remission Following ECT in Treatment-Resistant Depression
title_full Serum Mature BDNF Level Is Associated with Remission Following ECT in Treatment-Resistant Depression
title_fullStr Serum Mature BDNF Level Is Associated with Remission Following ECT in Treatment-Resistant Depression
title_full_unstemmed Serum Mature BDNF Level Is Associated with Remission Following ECT in Treatment-Resistant Depression
title_short Serum Mature BDNF Level Is Associated with Remission Following ECT in Treatment-Resistant Depression
title_sort serum mature bdnf level is associated with remission following ect in treatment-resistant depression
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870188/
https://www.ncbi.nlm.nih.gov/pubmed/35203890
http://dx.doi.org/10.3390/brainsci12020126
work_keys_str_mv AT psomiadesmarion serummaturebdnflevelisassociatedwithremissionfollowingectintreatmentresistantdepression
AT mondinomarine serummaturebdnflevelisassociatedwithremissionfollowingectintreatmentresistantdepression
AT galvaofilipe serummaturebdnflevelisassociatedwithremissionfollowingectintreatmentresistantdepression
AT mandaironnathalie serummaturebdnflevelisassociatedwithremissionfollowingectintreatmentresistantdepression
AT nourredinemikail serummaturebdnflevelisassociatedwithremissionfollowingectintreatmentresistantdepression
AT suaudchagnymariefrancoise serummaturebdnflevelisassociatedwithremissionfollowingectintreatmentresistantdepression
AT brunelinjerome serummaturebdnflevelisassociatedwithremissionfollowingectintreatmentresistantdepression